• Prevention of chemotherapy-related nausea & vomiting:
    • Adults: IV 0.25mg over 30 seconds *1 started 30 minutes before chemotherapy OR PO 0.5mg given1 our before chemotherapy
    • 1 month- 7 years: IV 20mcg/kg infused over 15 minutes *1
      • Started 30 minutes before chemotherapy
      • Max 1.5mg/dose
  • Prevention of postoperative nausea & vomiting:
    • IV 0.075mg infused over 10 seconds
    • Started immediately before anesthesia

Injection: 0.05mg/mL

  • For pediatric administration, do not use pre-filled syringe to administer a dose other than 0.25 g

Selective 5HT3 antagonist

It binds to 5-HT3 receptors both in peripheral and central nervous system with primary effects in GI tract

  • Headache
  • Constipation
  • QT prolongation (postop nausea/vomiting use)
  • Hypersensitivity to components
  • Coadministration with apomorphine
  • Apomorphine
  • Cisapride
  • Dronedarone
  • Levoketoconazole
  • Pimozide
  • Thioridazine

                          Drug Status

Availability Prescription only
Pregnancy Category B; Use with caution
Breastfeeding Use with caution
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Aloxi 0.2mg/5mL Injection 1's Modi Mundipharma Europa Healthcare
Palaton 0.25mg/5mL Injection 1’s Emcure Pharma Medcure Healthcare
Palaton 0.5mg Orodisperible tablet 10’s Emcure Pharma Medcure Healthcare
Palohalt 0.25mg/5mL Injection 1’s MSN Labs MSN Labs
Themiset 75mg/1.5mL Injection 1’s Themis Medicare Pharma Specialities
Themiset 0.25mg/5mL Injection 1’s Themis Medicare Pharma Specialities